Advertisement


Jakub Svoboda, MD, on Primary Mediastinal Large B-Cell, Diffuse Large B-Cell, and Gray Zone Lymphomas: Early-Phase Treatment Findings

2017 ASH Annual Meeting

Advertisement

Jakub Svoboda, MD, of the Abramson Cancer Center, University of Pennsylvania, discusses some encouraging phase I/II results on brentuximab vedotin with R-CHP chemotherapy as front-line treatment of CD30-positive primary mediastinal large B-cell, diffuse large B-cell, and gray zone lymphomas (Abstract 191).



Related Videos

Lymphoma

Andrew D. Zelenetz, MD, PhD, and Sattva S. Neelapu, MD, on NHL: Results From the ZUMA-1 Trial

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Sattva S. Neelapu, MD, of The University of Texas MD Anderson Cancer Center, discuss lo...

Lymphoma

Jia Ruan, MD, on Mantle Cell Lymphoma: Study Results on Lenalidomide and Rituximab

Jia Ruan, MD, of NewYork-Presbyterian/Weill Cornell Medical Center, discusses a 5-year follow-up analysis that showed lenalidomide and rituximab as initial treatment achieved a hig...

Lymphoma

Mark J. Roschewski, MD, on Burkitt Lymphoma: Clinical Trial Results on DA-EPOCH-R

Mark J. Roschewski, MD, of the National Cancer Institute, discusses phase II study findings that showed DA-EPOCH-R cures most adult patients with Burkitt lymphoma, irrespective of ...

Lymphoma

Carla Casulo, MD, on Follicular Lymphoma: Results From the FLASH Study

Carla Casulo, MD, of the James P. Wilmot Cancer Center, discusses findings on POD24 as a robust early clinical endpoint of poor survival in follicular lymphoma, using data from mor...

Lymphoma

Tycel J. Phillips, MD, on Intravascular DLBCL: Study of Patient Features and Outcomes

Tycel J. Phillips, MD, of the University of Michigan Medical School, discusses the findings of the largest retrospective study to date of patients with intravascular diffuse large ...

Advertisement

Advertisement



Advertisement